Print Page     Close Window     

SEC Filings

AC IMMUNE SA filed this Form 20-F on 03/21/2019
Entire Document


A quantitative sensitivity analysis for significant assumption as of December 31, 2018 is as shown below:


    Discount rate   Future salary increase   Future pension cost
Assumptions   +0.5% increase   -0.5% decrease   +0.5% increase   -0.5% decrease   +0.5% increase   -0.5% decrease
    in CHF thousands
Defined benefit obligation     16,250       19,906       18,475       17,441       18,826       17,346  
Impact on the net defined benefit obligation     1,692       (1,964)       (533)       501       (884)       596  


The sensitivity analyses above is subject to limitations and has been determined based on a method that extrapolates the impact on net defined benefit obligation as a result of reasonable changes in key assumptions occurring at the end of the reporting period.


16.Share-based compensation


Share based option awards


Through the year ended December 31, 2018, there are equity-based instruments outstanding that the Company has granted under four different plans.


The Company’s 2016 Share Option and Incentive Plan (“Plan”) was approved by the shareholders at the Ordinary Shareholder’s meeting in November 2016. The 2016 Plan authorizes the grant of incentive and non-qualified share options, share appreciation rights, restricted share awards, restricted share units, unrestricted share awards, performance share awards, performance-based awards to covered employees and dividend equivalent rights. The Company only grants equity-based instruments from this Plan as of December 31, 2018.


The following table summarizes equity settled share option grants since inception under each plan:


PLAN   Number of options awarded (since inception)   Vesting conditions   Contractual life of options
Share option plan A  


  At grant   15.5 years
Share option plan B  


  At grant   10.5 years
Share option plan C1  


  4 years’ service from grant date   10 years
2016 Share Option and Incentive Plan:            
Executives and Directors 538,764 4 years’ service from the date of grant, quarterly   10 years
Employees   222,405   4 years’ service from the date of grant, annually   10 years




© AC Immune 2015